Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Osteoporosis

Osteoporosis

Subtypes of Osteoporosis

Postmenopausal Osteoporosis 1

44 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Osteoporosis

164 trials tracked for Osteoporosis: 75 in phase 3 or 4 and 13 with published results. The most-cited published study has 344 citations.

164Trials tracked
75Phase 3 & 4
0Recruiting
13With published results
Phase distribution
Phase 4 30 Phase 3 45 Phase 2 37 Phase 1 10 Other / NA 42
  1. Phase 3 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis Completed · 344 cited
  2. Phase 3 Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms Completed · 179 cited
  3. Phase 3 Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031) Completed · 122 cited
  4. Phase 4 Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis Completed · 108 cited
  5. Phase 3 Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients Completed · 104 cited
  6. Phase 4 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement Completed · 47 cited
Show 44 more trials
  1. Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women Completed · 47 cited
  2. Phase 3 Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption Completed · 40 cited
  3. Phase 3 An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids Completed · 40 cited
  4. Phase 3 A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053) Completed · 22 cited
  5. Phase 4 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Completed · 12 cited
  6. Phase 4 Bone Health in Aging HIV Infected Women Completed · 8 cited
  7. Phase 3 Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM) Completed
  8. Phase 4 Bisphosphonate Therapy for Osteogenesis Imperfecta Completed
  9. Phase 4 A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture Completed
  10. Phase 4 Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study Completed
  11. Phase 4 Fracture (FX) Improvement With Teriparatide: FiX-IT Study Completed
  12. Phase 4 Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty Completed
  13. Phase 4 Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis Completed
  14. Phase 4 Effect of Atorvastatin on Bone-vascular Axis Completed
  15. Phase 4 Preventing Osteoporosis Using Denosumab Completed
  16. Phase 4 Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study Completed
  17. Phase 4 Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy Completed
  18. Phase 4 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis Completed
  19. Phase 4 Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI) Completed
  20. Phase 4 Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? Completed
  21. Phase 4 A Study of Teriparatide in Japanese Osteoporosis Patients Completed
  22. Phase 4 Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM) Completed
  23. Phase 4 Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use Completed
  24. Phase 4 Does Treatment of Hypovitaminosis D Increase Calcium Absorption? Completed
  25. Phase 4 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density Completed
  26. Phase 4 Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window? Completed
  27. Phase 4 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women Completed
  28. Phase 4 Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density Completed
  29. Phase 4 Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass Completed
  30. Phase 4 Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis Completed
  31. Phase 4 Does Omeprazole Decrease Intestinal Calcium Absorption? Completed
  32. Phase 4 Antiepileptic Drugs and Osteoporotic Prevention Trial Completed
  33. Phase 4 The Effect of Protein on Calcium Absorption and Gastric Acid Production Completed
  34. Phase 3 Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Completed
  35. Phase 3 Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy Completed
  36. Phase 3 Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women Completed
  37. Phase 3 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids Completed
  38. Phase 3 A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis Completed
  39. Phase 3 Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women Completed
  40. Phase 3 A Study for Patients With Osteoporosis Completed
  41. Phase 3 Vertebroplasty for the Treatment of Fractures Due to Osteoporosis Completed
  42. Phase 3 Denosumab Adherence Preference Satisfaction Study Completed
  43. Phase 3 Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329) Completed
  44. Phase 3 Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis Completed

Showing the 50 most-cited and recently-updated of 164 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Osteoporosis: what the trials found

Several bisphosphonates and other agents demonstrate efficacy in osteoporosis. Risedronate significantly reduced vertebral fractures compared to placebo (p=0.0229) 15 and improved BMD at hip and spine 16. Teriparatide significantly increased lumbar spine BMD (p<.0001) 12 and improved bone formation markers such as mineralizing surface in cancellous and endocortical compartments (p<0.001) 14. Denosumab significantly increased total hip and spine BMD (p=.007 and p=.014, respectively) 6. Zoledronic acid showed BMD changes over 6 months and 2 years 2. Atorvastatin altered OPG/RANK/RANKL expression and increased osteoprogenitor cells (p<0.05) 7. Raltegravir improved lumbar spine and hip BMD (p<0.0001) 17. Tetracycline demonstrated modeling-based bone formation in the femoral neck 3. Alendronate was studied in multiple trials 41113. Generic alendronate was evaluated 4. Risedronate/cholecalciferol combination was studied 8. Teriparatide was also investigated in additional trials 101820. Omeprazole 21 and esomeprazole 22 were studied, with esomeprazole affecting intestinal calcium absorption. Tenofovir-alafenamide-emtricitabine showed percent change in lumbar spine BMD 5. Denosumab discontinuation and switching was examined 1.

Bone mineral density improvements were observed across multiple agents. Teriparatide increased spine BMD from baseline to 3 and 6 months 18. Risedronate showed BMD changes at hip and spine 16. Denosumab increased total hip and spine BMD significantly 6. Zoledronic acid showed BMD changes at lumbar spine 2. Raltegravir improved lumbar spine and hip BMD 17. Atorvastatin increased osteoprogenitor cells 7. Tetracycline showed modeling-based formation 3. Esomeprazole affected calcium absorption 22. Tenofovir-alafenamide-emtricitabine showed BMD changes 5.

Adverse events and other outcomes were reported. Teriparatide was associated with hip pain in some patients 12. Risedronate reduced vertebral fractures 15. Denosumab showed BMD improvements 6. Zoledronic acid had BMD changes 2. Raltegravir maintained HIV viral load suppression 17. Omeprazole and esomeprazole were studied for calcium absorption 2122.

Recent results — preliminary, needs further review

  • Denosumab discontinuation and switching is a new area of investigation 1.
  • Atorvastatin's effect on OPG/RANK/RANKL and osteoprogenitor cells is a recent finding 7.
  • Tetracycline's modeling-based bone formation in femoral neck is a recent observation 3.
  • Tenofovir-alafenamide-emtricitabine's BMD changes in HIV patients is a recent study 5.
  • Raltegravir's BMD improvements in HIV patients is a recent finding 17.

For the clinician treating this condition

  • Bisphosphonates (risedronate, alendronate, zoledronic acid) and denosumab improve BMD and reduce fracture risk in osteoporosis.
  • Teriparatide increases bone formation markers and lumbar spine BMD.
  • Raltegravir and tenofovir-alafenamide-emtricitabine may improve BMD in HIV patients with osteoporosis.

AI synthesis of 20 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bibliometric Mapping Analysis Reveals Evolving Research Trends in Scoliosis and Osteoporosis Management
Orthopedics & Sports Medicine Sys. Review
Bibliometric Mapping Analysis Reveals Evolving Research Trends in Scoliosis and Osteoporosis Management Scoliosis and Osteoporosis Research Trends Mapped Over 20 Years
A comprehensive bibliometric analysis of over 1,000 publications highlights a significant shift toward bone quality assessment and risk stra…
A new review maps 20 years of scoliosis and osteoporosis research, revealing a shift toward bone quality and surgical outcomes.
Frontiers Jul 25, 2026
Gut microbiota interventions may modulate bone metabolism and influence progression of postmenopausal osteoporosis
OB/GYN & Women's Health Sys. Review
Gut microbiota interventions may modulate bone metabolism and influence progression of postmenopausal osteoporosis Gut bacteria may help prevent osteoporosis in older women
This systematic review explores how gut microbiota-based interventions, including probiotics and prebiotics, may impact bone health in postm…
A new review suggests probiotics and other gut-focused treatments could help protect bone health in postmenopausal women.
Frontiers Jul 4, 2026
The osteoimmune-brain axis links systemic inflammation and bone hormones to neurodegenerative pathology
Allergy & Immunology Sys. Review
The osteoimmune-brain axis links systemic inflammation and bone hormones to neurodegenerative pathology Immune system may link bone health and brain disease
This systematic review examines the role of the osteoimmune-brain axis, where the immune system mediates skeletal and cerebral pathology thr…
A new look at the body's immune system suggests a link between bone health and conditions like Alzheimer's and dementia.
Frontiers Jun 24, 2026
Locking plate fixation and arthroplasty are key treatments for osteoporotic proximal humeral fractures
Orthopedics & Sports Medicine Sys. Review
Locking plate fixation and arthroplasty are key treatments for osteoporotic proximal humeral fractures Mainstream Treatments for Complex Osteoporotic Shoulder Fractures
This systematic review summarizes mainstream treatments for elderly patients with complex osteoporotic proximal humeral fractures. Strategie…
New evidence helps doctors choose the best surgical options, such as locking plates or joint replacements, for elderly patients with complex…
Frontiers Jun 23, 2026
Circadian misalignment associated with increased risk of osteoporosis, sarcopenia, and osteoarthritis
Nutrition & Obesity Medicine Sys. Review
Circadian misalignment associated with increased risk of osteoporosis, sarcopenia, and osteoarthritis Circadian Disruption Linked to Bone and Muscle Loss
This narrative review examines the impact of circadian disruption on musculoskeletal health, specifically regarding bone loss, muscle protei…
Shift work and irregular eating may harm bones and muscles. A new review explains how.
Frontiers Jun 22, 2026
Chinese botanical drugs may improve bone metabolism by modulating the gut-bone axis in osteoporosis
Orthopedics & Sports Medicine Sys. Review
Chinese botanical drugs may improve bone metabolism by modulating the gut-bone axis in osteoporosis Chinese Botanical Drugs May Help Manage Osteoporosis via Gut Health
This systematic review examines how Chinese botanical drugs (CBDs) influence bone metabolism through gut microbiota remodeling and intestina…
New research suggests that Chinese botanical drugs may help manage osteoporosis by improving gut health and the connection between the gut a…
Frontiers Jun 20, 2026
CD8+ T cells and associated signaling pathways influence osteoclast formation and osteoblast differentiation in osteoporosis
Allergy & Immunology Sys. Review
CD8+ T cells and associated signaling pathways influence osteoclast formation and osteoblast differentiation in osteoporosis Immune Cells and Signaling Pathways Influence Bone Health in Osteoporosis
This narrative review synthesizes the role of CD8+ T cells and related cytokines like IFN-gamma, CCL5, and IL-33 in bone metabolism. The aut…
New research highlights how specific immune cells and signaling pathways may play a dual role in protecting or promoting bone loss in osteop…
Frontiers Jun 12, 2026
Novel osteoporosis therapies targeting osteoclast fusion and polarization show promise beyond bisphosphonates
Drug Pipeline Sys. Review
Novel osteoporosis therapies targeting osteoclast fusion and polarization show promise beyond bisphosphonates New osteoporosis treatments target bone-eating cells more safely
This narrative review examines emerging therapeutic strategies that target osteoclast fusion and polarization, including DC-STAMP/OC-STAMP n…
Future osteoporosis drugs may work by blocking the fusion of bone-destroying cells, offering a safer alternative to current treatments.
Frontiers Jun 5, 2026
Physical exercise therapy may support osteosarcopenia management in elderly patients according to this narrative review
Geriatrics & Aging Sys. Review
Physical exercise therapy may support osteosarcopenia management in elderly patients according to this narrative review Exercise may help fight bone and muscle loss in aging
This narrative review discusses physical exercise therapy for osteosarcopenia in the elderly population. The authors outline potential benef…
A new review suggests physical exercise could slow bone and muscle loss in older adults with osteosarcopenia.
Frontiers Jun 4, 2026
Network meta-analysis reveals optimal aerobic exercise frequency and intensity for improving bone mineral density in osteoporosis patients
Diabetes & Endocrinology Meta-analysis
Network meta-analysis reveals optimal aerobic exercise frequency and intensity for improving bone mineral density in osteoporosis patients Network meta-analysis finds aerobic exercise improves bone density in osteoporosis patients
A comprehensive network meta-analysis of 2,183 participants demonstrates that aerobic exercise significantly boosts bone mineral density acr…
A network meta-analysis of 2,183 participants shows aerobic exercise improves bone density better than control, with specific intensity and …
Frontiers Jun 3, 2026
Drug-induced osteoporosis mechanisms and gut microbiota links remain largely unresolved for most medication classes
Orthopedics & Sports Medicine Sys. Review
Drug-induced osteoporosis mechanisms and gut microbiota links remain largely unresolved for most medication classes Many common medicines might change gut bacteria and affect bone strength in older adults
This narrative review examines the association between medications such as glucocorticoids and aromatase inhibitors and gut microbiota alter…
Some drugs like antidepressants and seizure medicines can alter gut bacteria. Scientists are still studying if these changes hurt bones or c…
Frontiers Jun 1, 2026
Gut microbiome metabolites regulate bone health via SCFAs, bile acids, and tryptophan pathways
Orthopedics & Sports Medicine Sys. Review
Gut microbiome metabolites regulate bone health via SCFAs, bile acids, and tryptophan pathways Multi-omics approaches reveal new links between gut microbes and bone health
This narrative review synthesizes evidence that gut microbiome metabolites—SCFAs, bile acids, and tryptophan derivatives—regulate bone remod…
A narrative review suggests gut microbes may influence bone conditions like osteoporosis and osteoarthritis through specific metabolic pathw…
Frontiers May 29, 2026

Questions about Osteoporosis

Can MRI scans and machine learning predict osteoporosis and abnormal bone density?

Yes, MRI scans combined with machine learning can predict osteoporosis and abnormal bone density with high accuracy, often matching or exceeding CT-based methods.

Full answer →
Can VBQ scores and Hounsfield Units predict fractures after vertebral augmentation?

Yes, both VBQ scores and Hounsfield Units can predict fractures after vertebral augmentation, with VBQ showing slightly better sensitivity.

Full answer →
Does romosozumab improve bone strength in postmenopausal women with osteoporosis?

Yes, romosozumab improves bone strength in postmenopausal women with osteoporosis, as shown by increases in shear bone strength, volumetric BMD, and trabecular bone score in clinical trials.

Full answer →

All Osteoporosis Articles